CASE REPORT

A 3-year-old female was diagnosed with acute lymphoblastic leukemia (ALL), with intermediate risk (immunophenotype pre-B), when she was 23 months old. In order to start her chemotherapy, a central venous access device (subcutaneous port [SP]) was implanted in September 2009. The patient was treated with SHOP-05 (Spanish Pediatric Hematology Society-2005) protocols for high-risk ALL, and she was in complete remission after the induction phase and completed four consolidation and reinduction phases, as was mandatory. Near the end of the second year of maintenance, when she was receiving only oral mercaptopurine (50 mg/m2/daily) and intramuscular methotrexate (20 mg/m2/weekly), the patient had a fever peak 5 h after a blood collection from the SP. The patient was treated empirically with oral cefixime (8 mg/kg of body weight/daily) when the fever started because she had had a prior isolation documented as Klebsiella pneumoniae that was sensitive to cephalosporins, and since she was not neutropenic and had no other signs or symptoms of interest, outpatient treatment was tried first. We obtained one pediatric blood culture, which grew long, slightly curved, thin, nonbranching Gram-positive rods. Culture of blood samples after 48 h of incubation at 35°C ± 2°C in 5% CO2 on chocolate and blood agar plates. Interpretations were based on CLSI breakpoints for mycobacteria, nocardiae, and other aerobic actinomycetes but not breakpoints for meropenem (MIC > 32 μg/ml) and vancomycin (MIC, 2 μg/ml) because they were not assessed in this document. The isolate was susceptible to amikacin (MIC, 1 μg/ml), tobramycin (MIC, 4 μg/ml), ciprofloxacin (MIC, 0.25 μg/ml), clarithromycin (MIC, 0.125 μg/ml), and linezolid (MIC, 1 μg/ml) and resistant to amoxicillin-clavulanic acid (MIC > 256 μg/ml) and ceftiraxone (MIC > 32 μg/ml).

For 3 days, she received ertapenem intravenously (15 mg/kg/12 h), but due to both the onset of a generalized nonpurpuric rash and the results of susceptibility testing, ciprofloxacin (20 mg/kg/day in 2 doses) and amikacin (20 mg/kg/day) were then prescribed; the catheter was removed on the fourth day of admission. The patient improved and remained afebrile 24 h after treatment change and device removal. The treatment was completed after 7 days of ciprofloxacin and amikacin administration, and afterwards, she was treated with oral clarithromycin (15 mg/kg/day in two doses) for 15 days in her home. The device was sent for microbiological culture, but no growth was observed on brain heart infusion medium. No clinical relapse was observed during the next year, and she remains in complete uneventful remission.

In order to confirm T. pulmonis identification, additional phenotypic and molecular tests were performed. The isolate did not grow at 42°C, and the following results of sugars assimilation were obtained with the API 50 CH systems (bioMérieux, Marcy l’Etoile, France). The isolate was mannitol positive, inositol negative, D-sorbitol negative, arbutin negative, arbutin negative, inulin negative, D-melezitose negative, D-arabitol negative, and L-fucose positive. The available
TABLE 1 Sequence similarity values for 16S rRNA sequences and secA1 sequences of Tsukamuraella species and our clinical isolate of T. pulmonis, HUMV-11090126a

<table>
<thead>
<tr>
<th>Tsukamuraella species</th>
<th>T. paurometabola</th>
<th>T. pseudospumae</th>
<th>T. tyrosinosolvens</th>
<th>T. strandjordii</th>
<th>T. pulmonis</th>
<th>HUMV-11090126a</th>
</tr>
</thead>
<tbody>
<tr>
<td>T. paurometabola</td>
<td>99</td>
<td>91.5</td>
<td>90.4</td>
<td>ND</td>
<td>90</td>
<td>90.4</td>
</tr>
<tr>
<td>T. pseudospumae</td>
<td>99.3</td>
<td>99.5</td>
<td>96</td>
<td>ND</td>
<td>93.4</td>
<td>91.7</td>
</tr>
<tr>
<td>T. tyrosinosolvens</td>
<td>99.5</td>
<td>99.3</td>
<td>99.7</td>
<td>ND</td>
<td>92.1</td>
<td>91.2</td>
</tr>
<tr>
<td>T. strandjordii</td>
<td>99.5</td>
<td>99.6</td>
<td>99.7</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>T. pulmonis</td>
<td>99.5</td>
<td>99.6</td>
<td>99.7</td>
<td>99.5</td>
<td>98</td>
<td></td>
</tr>
<tr>
<td>HUMV-11090126b</td>
<td>99.6</td>
<td>99.6</td>
<td>99.7</td>
<td>99.7</td>
<td>100</td>
<td></td>
</tr>
</tbody>
</table>

a 16S rRNA sequences are in the lower left, and secA1 sequences are in the upper right. ND, no data. 16S rRNA GenBank accession numbers were as follows: for T. paurometabola, NR074458; for T. pseudospumae, NR042800; for T. tyrosinosolvens, AY238514; for T. strandjordii, AFA238283; and for T. pulmonis, ATCC741505 (the accession number for the secA1 gene sequences are indicated in the text).

b The 16S rRNA is 1,012 bp; the secA1 gene is 230 bp.

partial secA1 gene sequences of three Tsukamuraella species (deposited by researchers at Westmead Hospital in Sydney, Australia), namely, Tsukamuraella tyrosinosolvens (GenBank accession number GU179146), Tsukamuraella pseudospumae (GU179143), and Tsukamuraella pulmonis (GU179144), and the complete secA1 sequence of the Tsukamuraella paurometabola type strain, ATCC 8368 (CP001966), were aligned by using the Clustal W program (v. 1.81). Two candidate primers, Tsuka1 (5′-CTACCTGCGCGA CAACATG-3′) and Tsuka2 (5′-CTACCTGTCCTCTTGGCAGTG-3′), which correspond to T. paurometabola secA1 gene positions 546 to 564 and 756 to 775, respectively (GenBank accession no. CP001966, nucleotides 1106448 to 1109201), were designed by using primer 3.

The PCR amplification of the secA1 gene of our isolate (HUMV-11090126) (annealing temperature of 60°C) showed the predicted amplicon of 230 bp. Subsequent sequencing with the same primers and comparison of the obtained sequence with GenBank entries, by using the BLASTn algorithm, gave 98% homology with T. pulmonis (accession no. GU179144), followed by T. pseudospumae (GU179145) (91.7%), T. tyrosinosolvens (GU179145, GU179146, GU179147, GU179148, GU179149) (91.2%), and T. paurometabola (CP001966) (90.4%) (Table 1).

The genus Tsukamuraella includes aerobic Gram-positive and modified acid alcohol-fast-positive rods belonging to the aerobic actinomycetes, usually found in soil, sludge, and arthropods (1). Yassin et al. isolated and described the species of interest, T. pulmonis, in 1996 from the sputum of a 92-year-old woman with a history of lung tuberculosis (2).

T. pulmonis is a rare human pathogen associated with oncologic and immunosuppressed patients (3, 4), and a variety of infections have been associated with this bacterium: pneumonia (5), conjunctivitis (6), keratitis (7), and catheter-related bacteremia (3, 8). In our case, T. pulmonis was isolated from an immunosuppressed child in three different blood culture sets, but the primary source of the infection could not be identified. Even though the long-term central venous catheter culture was negative, the first fever peak was registered after blood was collected for a hematological analysis, and the patient improved as the catheter was removed. In consequence, it seems reasonable to consider this device associated with the beginning of episodes. Bouza et al. (9) performed a review of catheter-related bloodstream infections, and most of them required the withdrawal of the infected line, along with antibiotic treatment, to resolve the episodes.

Our isolate was susceptible to aminoglycosides, macrolides, and quinolones but resistant to amoxicillin-clavulanic acid, ceftriaxone, and presumably carbapenems. Other authors have shown a similar susceptibility pattern (3, 4, 10).

T. pulmonis and related species may well be underdiagnosed or misdiagnosed as a cause of significant infections owing to the difficulty of identifying the organism by phenotypic procedures (11). Two reports (4, 9) have described the same API Coryne code which we found for our isolate.

Aimed at identifying uncommon pathogens, most of all in immunocompromised hosts, 16S rRNA sequencing is a reasonably rapid and consistent molecular technique. However, in this case, the gene was not shown to be discriminative enough for the identification of Tsukamuraella spp., since the differences in the genes are minimal among the different species of the genus (Table 1) (9, 10). In contrast, an analysis of a region of the secA1 gene was shown to be suitable for discrimination among four important clinical species of Tsukamuraella, as it has been demonstrated for other clinically significant species of aerobic actinomycetes (12, 13).

We could not perform a comparison with Tsukamuraella strandjordii and Tsukamuraella inchonensis, the other species recovered from clinical specimens, because their sequences have not been deposited in GenBank. Nevertheless, in our case, the isolate could be differentiated from T. inchonensis because our species does not grow at 45°C and from T. strandjordii on the basis of its sugar utilization profile, since T. strandjordii uses inulin, arbutin, and D-melezitose as carbon sources, whereas our isolate does not (14, 15).

In conclusion, we present a case of bacteremia caused by T. pulmonis that was essentially identified by molecular methods, in particular, secA1 gene sequencing, and this gene was demon-
strated to be a good target for differentiation among the most relevant pathogenic species of this genus.

**Nucleotide sequence accession numbers.** The 16S rRNA sequence and the secA1 sequence of the *T. pulmonis* isolate were deposited in GenBank under accession numbers KP056257 and KP013182, respectively.

**ACKNOWLEDGMENT**

We are grateful to Caroline Ender for reviewing our English grammar.

**REFERENCES**